Search Results
10
Everything
Amplified Sciences earns CLIA certification for its first test to assess pancreatic cancer risk
February 19, 2025 09:01 ET
|
Purdue Research Foundation
WEST LAFAYETTE, Ind., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Amplified Sciences, a clinical-stage life sciences diagnostic company that develops tests for early, more accurate detection of challenging...
AIM ImmunoTech Releases Virtual Investor “What This Means Segment”
February 11, 2025 08:45 ET
|
AIM ImmunoTech Inc.
Tom Equels, CEO of AIM ImmunoTech and Professor Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, discuss the Phase 1b/2 clinical trial involving AIM’s Ampligen® (rintatolimod)...
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
February 06, 2025 07:00 ET
|
Immuneering Corporation
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen® and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
February 05, 2025 08:00 ET
|
AIM ImmunoTech Inc.
Safety Committee approval based on positive Phase 1 safety data demonstrating the combination therapy to be generally well-tolerated with no severe treatment-related adverse events or dose-limiting...
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 03, 2025 16:05 ET
|
Immuneering Corporation
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus
January 22, 2025 08:30 ET
|
FN Media Group LLC
PALM BEACH, Fla., Jan. 22, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The demand for effective pancreatic cancer treatments is and has been undeniably high. The growing number of...
University Cancer & Blood Center physicians recognized among Atlanta’s Top Doctors in Modern Luxury Medicine + Doctors magazine
January 15, 2025 14:14 ET
|
University, Cancer and Blood Center
Four physicians from University Cancer & Blood Center are recognized as Top Doctors in Modern Luxury Medicine + Doctors magazine.
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
January 13, 2025 08:00 ET
|
Immuneering Corporation
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms
January 07, 2025 07:00 ET
|
Immuneering Corporation
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
December 26, 2024 09:00 ET
|
FN Media Group LLC
PALM BEACH, Fla., Dec. 26, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The breast cancer drugs market is experiencing rapid expansion due to the diverse applications of drugs in...